LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported second quarter 2025 financial and ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Management expects continued revenue growth driven by robust FILSPARI demand in IgA nephropathy and potential additional milestone payments. Cline said, "we expect continued revenue growth driven by ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ: TVTX) reported stronger-than-expected second quarter 2025 financial results on Wednesday, driven by significant growth in FILSPARI sales, sending ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have enlarged exposure to ...

SAN DIEGO, June 03, 2025--Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

FILSPARI is already approved for slowing kidney function decline in adults with IgA nephropathy (IgAN) and could become the first FDA-approved treatment for FSGS if approved. Additionally, Travere ...